Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.77 |
| ▸ | HTR1A | P08908 | 5/20 | 0.77 |
| ▸ | HTR2C | P28335 | 4/20 | 0.77 |
| ▸ | HTR6 | P50406 | 4/20 | 0.77 |
| ▸ | HTR2B | P41595 | 3/20 | 0.77 |
| ▸ | HTR1B | P28222 | 3/20 | 0.77 |
| ▸ | HTR7 | P34969 | 3/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.77 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.77 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.77 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.77 |
| ▸ | HRH1 | P35367 | 2/20 | 0.77 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.77 |
| ▸ | HTR5A | P47898 | 2/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N,N-Dimethyltryptamine SCHEMBL25174555 | 0.90 | HTR2A (0.65) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL25180279 | 0.88 | HTR1A (1.00) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL22736735 | 0.87 | MEN1 (0.65) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL22736730 | 0.87 | HTR2A (0.71) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL22772906 | 0.87 | MEN1 (0.65) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL27221709 | 0.83 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL335710 | 0.83 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL29350959 | 0.83 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL23069121 | 0.81 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR6HTR2B | |
| N,N-Dimethyltryptamine SCHEMBL25285129 | 0.81 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042564-B2 | Therapeutic solid dosage forms | CYBIN UK LTD (GB) | 2024-07-23 | — | — | US | claimed |
| US-11771681-B2 | Therapeutic compounds | SMALL PHARMA LTD (GB) | 2023-10-03 | — | — | US | claimed |
| US-20230149293-A1 | INJECTABLE AND INHALABLE FORMULATIONS | CYBIN UK LTD (GB) | 2023-05-18 | — | — | US | claimed |
| EP-4149460-A1 | THERAPEUTIC SOLID DOSAGE FORMS | Small Pharma Ltd (GB) | 2023-03-22 | — | — | EP | claimed |
| US-20220313660-A1 | INJECTABLE FORMULATIONS | SMALL PHARMA LTD (GB) | 2022-10-06 | — | — | US | claimed |
| US-20220168275-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2022-06-02 | — | — | US | claimed |
| EP-3826632-B1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2022-05-18 | — | — | EP | claimed |
| CN-114096246-A | Therapeutic compositions comprising deuterated or partially deuterated N, N-dimethyltryptamine compounds | 斯玛尔药物有限公司 | 2022-02-25 | — | — | CN | claimed |
| US-20210378969-A1 | THERAPEUTIC SOLID DOSAGE FORMS | SMALL PHARMA LTD. (GB) | 2021-12-09 | — | — | US | claimed |
| EP-3902541-A2 | DEUTERATED COMPOUNDS | Small Pharma Ltd (GB) | 2021-11-03 | — | — | EP | claimed |
| WO-2021116503-A2 | DEUTERATED COMPOUNDS | SMALL PHARMA LTD (GB) | 2021-06-17 | — | — | WO | claimed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | claimed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4654967-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS BY PARENTERAL ADMINISTRATION OF A SINGLE, EFFECTIVE PARENTERAL DOSE OF A SHORT-ACTING PSYCHEDELIC AGENT | Cybin UK Ltd (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-20250262145-A1 | INJECTABLE AND INHALABLE FORMULATIONS | CYBIN UK LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-3826632-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | Small Pharma Ltd (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | disclosed |
| WO-2020245133-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042564-B2 | Therapeutic solid dosage forms | SLC6A4, HTR5A, SLC6A3 | HTR2A 10/4885HTR1A 7/4885HTR2C 6/4885 |
| US-20250262145-A1 | INJECTABLE AND INHALABLE FORMULATIONS | HTR5A, HTR1B, HTR2B | HTR2A 21/4885HTR1A 7/4885HTR2C 5/4885 |
| US-11771681-B2 | Therapeutic compounds | HTR5A, DRD4, DRD2 | HTR2A 44/4885HTR1A 25/4885HTR2C 22/4885 |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | HTR2A 2/4885HTR1A 11/4885HTR2C 3/4885 |
| US-20220313660-A1 | INJECTABLE FORMULATIONS | SLC6A4, HTR5A, SLC6A3 | HTR2A 15/4885HTR1A 17/4885HTR2C 9/4885 |
| US-20200390746-A1 | Therapeutic Compounds | HTR5A, DRD4, DRD2 | HTR2A 44/4885HTR1A 25/4885HTR2C 22/4885 |
| US-20210378969-A1 | THERAPEUTIC SOLID DOSAGE FORMS | SLC6A4, HTR5A, SLC6A3 | HTR2A 10/4885HTR1A 7/4885HTR2C 6/4885 |
| US-20230149293-A1 | INJECTABLE AND INHALABLE FORMULATIONS | HTR5A, HTR1B, HTR2B | HTR2A 21/4885HTR1A 7/4885HTR2C 5/4885 |
| US-20220168275-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | DRD2, CHRND, HTR5A | HTR2A 28/4885HTR1A 15/4885HTR2C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.